Continue to Innovate for better Health
Press Release No. 56/KFCP-DIR/PR/XII/20
Jakarta, December 23, 2020 – PT Kalbe Farma Tbk (“Kalbe” or the “Company”) held the Company's Extraordinary General Meeting of Shareholders (“EGMS”) which was held on 23 December 2020 at the Kalbe Business Innovation Center Building, Pulogadung, Jakarta.
In order to reduce the impact of Covid-19, Kalbe will continue to innovate in providing medicinal products, vitamins, supplements, medical devices, laboratory tests, diagnostic tests, clinical trials of vaccines and herbal products for the public. Kalbe continues to strictly implement internal and external health protocols and educates the market through various channels.
In the EGMS, the Company has obtained the approval of the shareholders on the following agenda:
1. Changes in the composition of the members of the Board of Directors so that the composition of the Company’s Board of Directors and Board of Commissioners as follows until the end of terms in 2023:
President Commissioner: BERNADETTE RUTH IRAWATI SETIADY;
Commissioner: SANTOSO OEN;
Commissioner: FERDINAND ARYANTO;
Commissioner: RONNY HADIANA;
Independent Commissioner: LUCKY SURJADI SLAMET;
Independent Commissioner: LILIS HALIM;
Independent Commissioner: ADI HARSONO;
President Director: VIDJONGTIUS;
Director: DJONNY HARTONO TJAHYADI;
Director: BUJUNG NUGROHO;
Director: SIE DJOHAN;
Director: BERNADUS KARMIN WINATA
2.Approval of Amendments and Statement on the Company's Articles of Association which include Amendments to Article 3 of the Articles of Association concerning the Company's Purposes and Objectives with the addition of the main business activities in the Traditional Medicinal Products Industry for Humans, Adjustment of provisions in the Articles of Association of the Company regarding the Implementation of Meetings of the Board of Directors and the Board of Commissioners which can be conducted simultaneously through electronics and Adjustments to the Company's Articles of Association in connection with the Financial Services Authority Regulations No.15/ POJK.04/2020 concerning Planning and Implementation of General Meeting of Shareholders of Public Companies, Financial Services Authority Regulation No.16/POJK.04/2020 concerning the Implementation of the General Meeting of Shareholders of Public Companies Electronically, and Financial Services Authority Regulation No.14 / POJK.04 / 2019 concerning Increase in Capital for Public Companies by Providing Pre-emptive Rights.
Towards the end of 2020, which healthy financial position, Kalbe has distributed an interim dividend of IDR 281.3 billion to shareholders on December 18, 2020, so that each share will receive a cash dividend of IDR 6. The Company remains optimistic about future growth potential and will spend the budgeted capital expenditures, which is IDR 1 trillion. Going forward, the Company will strive to maintain its policy of distributing dividends of around 45-55% of net income, taking into account the Company's development plans and funding needs.
With full caution towards 2021, Kalbe will maintain optimism, continue to try and follow the gradual economic recovery carried out by the government. Hopefully year 2021 will be better than year 2020.
Kalbe at a Glance
PT Kalbe Farma Tbk. (“Kalbe”) was established in 1966 and is one of the largest publicly-listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions managing a broad and strong portfolio of brands; Prescription Pharmaceuticals Division, Consumer Health Division comprising over-the-counter drugs, as well as supplement drink and ready to drink products, Nutritionals Division, and Distribution & Logistics Division. Kalbe currently has 43 subsidiaries and 15 production facilities with international standards, employed around 16,000 employees and have 76 branches of distribution & logistics across Indonesia. Since 1991, Kalbe’s shares have been listed on the Indonesia Stock Exchange (IDX: KLBF).